← All trials
NCT02344628
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2015
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 583
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- University of LondonOverall official - principal investigator
- World Health OrganizationCollaborator
- Kwame Nkrumah University of Science and TechnologyCollaborator
- Papua New Guinea Institute of Medical ResearchCollaborator
- Ghana Health ServicesCollaborator
- Noguchi Memorial Institute for Medical ResearchCollaborator
- University of Health and Allied Sciences, GhanaCollaborator
- University of BarcelonaCollaborator
- Government of Papua New GuineaCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.